Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV DOI Creative Commons
Melania Degli Antoni, Giovanni Maifredi,

Samuele Storti

et al.

Infection, Journal Year: 2024, Volume and Issue: unknown

Published: May 3, 2024

Abstract Background Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about infection on risk post-COVID-19 conditions (PCCs) onset. We aim to assess incidence PCC PLWH factors associated its occurrence. Methods performed a retrospective, observational study including all > 18 years registered Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, viro-immunological parameters from February 2020 until May 2022. Persistence self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, neuro-behavioral symptoms) was evaluated after 3 months by telephone-administered questionnaire. estimated associations between variables outcomes through univariate multivariable logistic models. Results In period, 653 were diagnosed (17.1%). observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, (0.5%) deaths. interviewed 510/653 (78%), 178 (PCCs prevalence 34.9%; CI 95% 30.7–39.2) reported persistent symptoms. Asthenia/fatigue most symptom (60/178), followed muscular pain (54/178). multivariate regression model, there lower PCCs males respect females (adjusted OR = 0.64; 0.99–3.66), while hospitalization during acute an increased 1.9; 0.99–3.66). Notably, no variable modified Conclusions highlights substantial among PLWH, three post-SARS-CoV-2 infection, independent features or status.

Language: Английский

Prevalence, risk factors, and impact of long COVID in a socially vulnerable community in Brazil: a prospective cohort study DOI Creative Commons
Pedro Azambuja, Leonardo dos Santos Lourenço Bastos, Amanda De Araújo Batista Da Silva

et al.

The Lancet Regional Health - Americas, Journal Year: 2024, Volume and Issue: 37, P. 100839 - 100839

Published: July 17, 2024

Long COVID is an emerging global public health issue. Socially vulnerable communities in low- and-middle-income countries were severely impacted by the pandemic and are underrepresented research. This prospective study aimed to determine prevalence of long COVID, its impact on health, associated risk factors one such community Rio de Janeiro, Brazil.

Language: Английский

Citations

3
The Ambivalence of Post COVID-19 Vaccination Responses in Humans DOI Creative Commons
Radha Gopalaswamy, Vivekanandhan Aravindhan, Selvakumar Subbian

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(10), P. 1320 - 1320

Published: Oct. 17, 2024

The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has prompted a massive global vaccination campaign, leading to the rapid development and deployment of several vaccines. Various COVID-19 vaccines are under different phases clinical trials include whole virus or its parts like DNA, mRNA, protein subunits administered directly through vectors. Beginning in 2020, few mRNA (Pfizer-BioNTech BNT162b2 Moderna mRNA-1273) adenovirus-based (AstraZeneca ChAdOx1-S Janssen Ad26.COV2.S) were recommended WHO for emergency use before completion phase 3 4 trials. These mostly two three doses at defined frequency between doses. While these vaccines, mainly based on viral nucleic acids conferred protection against progression SARS-CoV-2 infection into COVID-19, prevented death due disease, their also been accompanied plethora side effects. Common effects localized reactions such as pain injection site, well systemic fever, fatigue, headache. symptoms generally mild moderate resolve within days. However, rare but more serious have reported, including allergic anaphylaxis and, some cases, myocarditis pericarditis, particularly younger males. Ongoing surveillance research efforts continue refine understanding adverse effects, providing critical insights risk-benefit profile Nonetheless, overall safety supports continued combating with regulatory agencies health organizations emphasizing importance preventing COVID-19's outcomes. In this review, we describe types summarize various autoimmune inflammatory response(s) manifesting predominantly cardiac, hematological, neurological, psychological dysfunctions. incidence, presentation, risk factors, diagnosis, management possible mechanisms contributing discussed. review highlights potential ambivalence human response post-COVID-19 necessitates need mitigate

Language: Английский

Citations

3
COVID-19 Booster Vaccination Status and Long COVID in the United States: A Nationally Representative Cross-Sectional Study DOI Creative Commons
Jamie L. Romeiser,

Kelsey Schoeneck

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 688 - 688

Published: June 20, 2024

Early studies have found that the initial COVID-19 vaccination series was protective against severe symptoms and long COVID. However, few explored association of booster doses on disease outcomes This cross-sectional analysis used data from 2022 US National Health Interview Survey to investigate how status correlates with infection severity COVID among previously infected individuals. Participants were categorized into three groups: those who had received at least one booster, only complete series, either an incomplete or no vaccinations. Out 9521 survey respondents reported a past positive test, 51.2% experienced moderate/severe infections, 17.6% Multivariable regression models revealed receiving shot associated lower odds experiencing (aOR = 0.78,

Language: Английский

Citations

2
COVID-19 vaccination perspectives among patients with Long COVID: A qualitative study DOI Creative Commons
Sarah R. MacEwan, Saurabh Rahurkar, Will L. Tarver

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 26, 2024

Individuals who have Long COVID may unique perspectives about COVID-19 vaccination due to the significant impact that has had on their lives. However, little is known specific among this patient population. The goal of our study was improve understanding vaccines individuals with COVID. Interviews were conducted patients receiving care at a post-COVID recovery clinic. Deductive thematic analysis used characterize participant according vaccine acceptance continuum framework, which recognizes spectrum from refusal. From interviews 21 patients, we identified across acceptance. These included prevent future illness, concerns side effects symptoms, and refusal perceived natural immunity. A limitation these are one In conclusion, demonstrates some uncertain boosters but also be amenable conversations Patient should considered when communicating recommendations for vaccinations

Language: Английский

Citations

2
Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV DOI Creative Commons
Melania Degli Antoni, Giovanni Maifredi,

Samuele Storti

et al.

Infection, Journal Year: 2024, Volume and Issue: unknown

Published: May 3, 2024

Abstract Background Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about infection on risk post-COVID-19 conditions (PCCs) onset. We aim to assess incidence PCC PLWH factors associated its occurrence. Methods performed a retrospective, observational study including all > 18 years registered Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, viro-immunological parameters from February 2020 until May 2022. Persistence self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, neuro-behavioral symptoms) was evaluated after 3 months by telephone-administered questionnaire. estimated associations between variables outcomes through univariate multivariable logistic models. Results In period, 653 were diagnosed (17.1%). observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, (0.5%) deaths. interviewed 510/653 (78%), 178 (PCCs prevalence 34.9%; CI 95% 30.7–39.2) reported persistent symptoms. Asthenia/fatigue most symptom (60/178), followed muscular pain (54/178). multivariate regression model, there lower PCCs males respect females (adjusted OR = 0.64; 0.99–3.66), while hospitalization during acute an increased 1.9; 0.99–3.66). Notably, no variable modified Conclusions highlights substantial among PLWH, three post-SARS-CoV-2 infection, independent features or status.

Language: Английский

Citations

2